Biotechnology - Immunologicals

Filter

Current filters:

Immunologicals

Popular Filters

201 to 225 of 2201 results

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

04-02-2014

A UK-based mobile human monitoring company is making waves in health care as it aims to revolutionize…

BiotechnologyInterviewsPharmaceuticalResearchUK

Biogen’s MS drug Tecfidera approved in EU

Biogen’s MS drug Tecfidera approved in EU

03-02-2014

US biotech firm Biogen Idec’s Tecfidera (dimethyl fumarate) has been approved by the European Commission…

Biogen IdecBiotechnologyEuropeNeurologicalRegulationTecfidera

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Celgene profits hit by higher R&D, acquisition costs

Celgene profits hit by higher R&D, acquisition costs

31-01-2014

US biotech major Celgene reported financial results for the fourth-quarter and full-year 2013, with final…

BiotechnologyCelgeneFinancial

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Fluidigm and DVS Sciences announce merger worth $207.5 million

30-01-2014

US-based microfluidic systems developer Fluidigm Corporation (NASDAQ:FLDM) has entered into a definitive…

BiotechnologyMergers & AcquisitionsUSA

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

30-01-2014

In a series of letters to be sent to state Medicaid directors starting this week, Michael Weinstein,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingSovaldiUSA

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

29-01-2014

US biotech firm Biogen Idec reported full year and fourth quarter 2013 results that beat consensus Wall…

Biogen IdecBiotechnologyFinancialTecfidera

Sanofi and Transgene launch construction phase of joint bioproduction platform

Sanofi and Transgene launch construction phase of joint bioproduction platform

29-01-2014

French drug major Sanofi and biotech firm Transgene have launched the construction phase of the manufacturing…

BiotechnologyFranceOncologyProductionSanofiTransgene

Amgen announces top-line results from Phase III trial of evolocumab

Amgen announces top-line results from Phase III trial of evolocumab

29-01-2014

USA-based Amgen announced that the Phase III LAPLACE-2 trial evaluating evolocumab (AMG 145) in combination…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen again tops analysts’ forecasts as profits rise 30%

Amgen again tops analysts’ forecasts as profits rise 30%

29-01-2014

Amgen, the world’s largest independent biotech firm, for the fifth reporting quarter beat analysts’…

AmgenBiotechnologyFinancial

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

28-01-2014

The US Food and Drug Administration’s Allergenic Products Advisory Committee has voted that the available…

Alk-AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

Gilead announces three promotions in senior management team

Gilead announces three promotions in senior management team

28-01-2014

US biotech major Gilead Sciences (Nasdaq: GILD) has announced several promotions within the company's…

BiotechnologyBoardroomGilead SciencesUSA

NW Bio to expand manufacturing of DCVax products

27-01-2014

US biotech firm Northwest Biotherapeutics has entered into a set of agreements for large-scale expansion…

BiotechnologyDCVaxEuropeNorth AmericaNorthwest BiotherapeuticsProductionRegulationUSA

Chelsea Therapeutics names Joseph Oliveto as president and CEO

Chelsea Therapeutics names Joseph Oliveto as president and CEO

27-01-2014

US biotech firm Chelsea Therapeutics’ (Nasdaq: CHTP) has named Joseph Oliveto as president and chief…

BiotechnologyBoardroomChelsea TherapeuticsUSA

TiGenix to sell Dutch manufacturing facility to PharmaCell

24-01-2014

Belgian cell therapy firm TiGenix has signed an agreement for the sale of its state-of-the-art Dutch…

BiotechnologyChondroCelectMergers & AcquisitionsNorthern EuropePharmaCellProductionTiGenix

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

BioLineRx gains orphan status for novel stem cell mobilization treatment

BioLineRx gains orphan status for novel stem cell mobilization treatment

23-01-2014

Israeli drug developer BioLineRx has received notice from the US Food and Drug Administration confirming…

BioLineRxBiotechnologyBL-8040Rare diseasesRegulationResearch

201 to 225 of 2201 results

Back to top